# The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

> **NCT05005741** · PHASE4 · UNKNOWN · sponsor: **Second Xiangya Hospital of Central South University** · enrollment: 120 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2
- Overweight or Obesity

## Interventions

- **DRUG:** Beinaglutide
- **DRUG:** Dulaglutide

## Key facts

- **NCT ID:** NCT05005741
- **Lead sponsor:** Second Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-03-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05005741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05005741, "The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05005741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*